CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Soft Tissue Sarcoma
Special Reports in Personalized Cancer Care
Online Continuing Education Activities
SELECT A TOPIC
<< View More Conferences
2016 Multidisciplinary Head and Neck Cancer Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Nussenbaum on Organ Preservation for Patients With Larynx Cancer
Dr. Schoenfeld on Immunologic Effects of Chemotherapy and Radiation in Head and Neck Cancer
Dr. Cohen on Lenvatinib in First- or Second-Line Thyroid Cancer
Oncology Conference Articles
Immunotherapy Continues to Advance in Head and Neck Cancer
An early-stage trial is examining the addition of nivolumab to a cetuximab regimen in head and neck squamous cell carcinoma.
Pazopanib/Cetuximab Combo Shows Promising Efficacy in Advanced HNSCC
The combination of pazopanib (Votrient) and cetuximab (Erbitux) showed a disease control rate of 77% in patients with recurrent or metastatic head and neck squamous cell carcinoma, including patients with cetuximab- or platinum-resistant disease.
Cetuximab Improves Long-Term Control in HPV-Negative Head and Neck Cancer
Among patients with HPV-negative, locoregionally advanced head and neck squamous cell carcinoma with a poor prognosis, adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy produced long-term control.
Martins on Lenvatinib's Significance in Differentiated Thyroid Cancer
Renato G. Martins, MD, discusses the impact of lenvatinib in patients with differentiated thyroid cancer, how and when it should be used in clinical practice, and the future potential for the agent.
Biomarkers Indicate Survival Benefit With Afatinib in HNSCC
Both progression-free and overall survival with second-line afatinib (Gilotrif) in recurrent or metastatic head and neck squamous cell carcinoma are associated with several biomarkers.
Induction Chemo Offers No OS Benefit for Locally Advanced Head and Neck Cancer
The use of induction chemotherapy for advanced head and neck squamous cell carcinoma does not improve overall survival.
Social Isolation, Financial Toxicity Equate to Risk Factors in Head and Neck Cancer
Patients with locally advanced head and neck cancer should be screened for social isolation and financial hardship, as these factors play a role in their ability to stay on medication, minimize hospital stays, and achieve optimal health outcomes.
HPV+ Oropharyngeal Cancer Recurrence Typically Detected Within 6 Months of Treatment
In patients treated with definitive radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma, most recurrences can be detected via imaging at 3 months and physical examinations during the first 6 months after treatment.
Chemoradiation Improves OS for Elderly Patients With Head and Neck Cancers
Concurrent chemoradiation significantly improved overall survival compared with radiation therapy alone for elderly patients with locally advanced head and neck cancers.
Smokers With HPV-Positive Oropharyngeal Cancer Accumulate Tobacco-Associated Mutations
Tobacco-associated mutations accumulate over time in smokers with HPV-positive oropharyngeal squamous cell cancer, resulting in less dependence on E6/E7 and other HPV-associated mutations.
FDA Approvals in Breast Cancer and Hodgkin Lymphoma, 2017 SGO Highlights, and More
FDA Approves Avelumab for Merkel Cell Carcinoma
CRISPR Builds More Powerful CAR T Cells
PD-1 and IDO Inhibitor Combo Slated to Change Practice in Melanoma
New Standards Are Emerging for Follicular Lymphoma and CLL
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2017
Intellisphere, LLC. All Rights Reserved.